Search
Karyopharm Therapeutics Inc
KPTIAdd to Watchlist
0.832USD
+0.352+73.33%
Close 10-28 16:00（ET）
18.87MMarket Cap
LossP/E TTM
After-hours 19:59 (ET)0.800USD-0.031-3.73%
After-hours 19:59 (ET)Karyopharm Therapeutics Inc (KPTI) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts giving stock ratings to Karyopharm Therapeutics Inc in the past month.
Buy
1 Strong Buy
3 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
7.250USD+1403.84%
KPTI Analyst Recommendation Trends
In the current month, KPTI has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. KPTI average Analyst price target in the last month is 7.250.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
1
1
1
2
2
2
2
2
3
3
3
4
4
4
4
4
1
1
2
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
6
7
7
7
7
7
KPTI Analyst Rating for Peer Comparison
Updated: Oct 27, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
9
17
11
1
0
38
Amgen Inc
AMGN
4
9
19
3
1
36
Eli Lilly and Co
LLY
10
19
3
1
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Financial Forecasting
Based on analysts' estimates, KPTI EPS is projected to reach -0.946 in FY2026Q3, following reported EPS of -2.316 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.99
-1.43
-1.28
-0.95
-0.85
Actual
-5.68
-1.02
-2.32
--
--
Surprise
-185.03%
+28.80%
-81.42%
--
--
FAQs
What is Karyopharm Therapeutics Inc's expected revenue for the next quarter?
Karyopharm Therapeutics Inc's expected revenue is 33.55M.
What is Karyopharm Therapeutics Inc's price target?
Analysts forecast that Karyopharm Therapeutics Inc's price target is USD 7.25, with the highest forecast at USD 11.00 and the lowest forecast at USD 3.00.
How have Karyopharm Therapeutics IncKPTI's recent earnings per share performed?
The market expectation was USD -2.32, while Karyopharm Therapeutics IncKPTI's earnings per share (EPS) for the previous quarter was USD -1.02. EPS for the next quarter is expected at USD -0.95.
What is the analyst rating for Karyopharm Therapeutics Inc?
Based on the ratings of Karyopharm Therapeutics Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.